UNSPSC 51144204: Pemoline

This classification denotes a cns stimulant with the molecular formula C9H8N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 7GAQ2332NK, chemically known as 4-oxazolidinone, 2-imino-5-phenyl- but more generally known as pemoline, which bears US NIH Compound Identifier 4723. European Medicines Agency schedules Pemoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09657MIG.

UNSPSC 51144204 Pemoline is a Commodity code that nominally covers a specific pharmaceutical compound, but recent state and local solicitations tagged with this code show no actual procurement activity for pemoline itself. Instead, the opportunities reveal purchasing of broader pharmaceutical and health-supply categories: naloxone and drug deactivation systems, therapeutic pharmacy program implementation, and generic multi-source pharmaceuticals and over-the-counter products. State and local buyers issuing under this code span county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and cooperative purchasing consortiums serving multiple jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance, with participation from Oregon). The mismatch between the code's nominal scope and actual purchasing intent signals that this code may be a catch-all classification for pharmaceutical acquisitions rather than a dedicated line for pemoline-specific procurement.

Recent activity clusters in the Southeast and Midwest. Seminole County issued an IFB (IFB60459723LAS, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to Sanford, Florida; the procurement included standard compliance requirements (drug-free workplace, E-Verify, commercial general liability and workers' compensation insurance) and potential FEMA funding. Texas Health and Human Services Commission posted an RFI (HHS0017013, April 3, 2026) to gather vendor capabilities for a direct-to-manufacturer prescription program, seeking information about vendors' experience with self-insured employers and negotiated net pricing models outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP (S1070000015802, due March 26, 2026) establishing multiple contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers, with awards effective July 1, 2026 and evaluation weighted 75 percent on price competitiveness, 10 percent on fixed pricing, and 5 percent each on administrative compliance, EDI capability, and administrative fee structure. No explicit set-asides or disadvantaged-enterprise restrictions appear in the available documentation.